Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05002959

TESS V3 Modular Total Shoulder System PMCF

Retrospective and Prospective, Multicenter Study on T.E.S.S.® V3 (Implants and Instrumentation)

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
67 (actual)
Sponsor
Zimmer Biomet · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a multicenter, retrospective and prospective, non-controlled post market surveillance study. The objectives of this study are to confirm safety, performance and clinical benefits of the T.E.S.S.® Version 3 Anatomic and Reverse Modular Total shoulder prosthesis and its instrumentation.

Detailed description

The T.E.S.S.® (Total Evolutive Shoulder System) was developed to provide, with one instrumentation, a complete solution for all indications for shoulder arthroplasty: centered and eccentric rheumatoid osteoarthritis, necrosis, proximal fracture and mal-union of the humeral head. The T.E.S.S.® Modular system can be used in anatomic or reverse configurations with or without the use of a stem, providing a solution for hemi-arthroplasty, total shoulder arthroplasty and revision. The same instrumentation allows implantation of all versions of the T.E.S.S.®. A maximum of 5 study centers will be involved in Europe. A total number of 146 implants, 73 T.E.S.S.® anatomic and 73 T.E.S.S.® reverse, will be included into the study. Each clinical site will be allowed to enroll a maximum 88 patients (60% of the total study cohort). Ethics Committee (EC) approval has to be obtained prior to conducting this study. All potential subjects will be required to participate in an informed consent process and sign the EC approved written informed consent prior to study enrollment.

Conditions

Interventions

TypeNameDescription
DEVICEAnatomic TESS V3Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Anatomic configuration.
DEVICEReverse TESS V3Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Reverse configuration.

Timeline

Start date
2022-02-01
Primary completion
2026-10-01
Completion
2026-12-01
First posted
2021-08-12
Last updated
2025-09-08

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT05002959. Inclusion in this directory is not an endorsement.